Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.
Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...
Debra OConnell will become chairman of Disney Entertainment Television, while Disney's gaming business, led by Sean Shoptaw, ...
Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...
Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an ...
Scientists have developed a powerful new computational method that could accelerate the search for next-generation materials ...
Structure Therapeutics said on Monday its pill helped patients lose up to 16.3% of their weight, strengthening its bid to challenge Eli Lilly and Novo Nordisk in the increasingly competitive race ...
TORONTO, ON / ACCESS Newswire / March 13, 2026 / Canada is experiencing a quiet revolution in the way it builds. From ...
Successful group work in middle and high school requires thoughtful design. These strategies help teachers structure ...
SpaceX is reportedly eyeing a dual-class share structure for its highly anticipated IPO later this year. The move would let billionaire founder Elon Musk maintain iron-grip control over the rocket ...
Did our AI summary help? SpaceX is considering a dual-class share structure in its planned IPO this year, according to people familiar with the matter, mirroring a strategy its billionaire founder ...
FILE PHOTO: SpaceX's logo and an Elon Musk photo are seen in this illustration created on December 19, 2022. REUTERS/Dado Ruvic/Illustration/File Photo Feb 13 (Reuters) - Elon Musk's SpaceX is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results